Allogene Therapeutics (ALLO) EBT (2018 - 2026)
Allogene Therapeutics (ALLO) reported EBT of -$145.2 million for Q1 2026, down 96.88% on a YoY basis from -$4.7 billion in Q1 2025, and down 271.79% sequentially from -$39.1 million in Q4 2025.
Allogene Therapeutics (ALLO) EBT (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of EBT data on file, last reported at -$145.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 96.88% year-over-year to -$145.2 million; the trailing twelve-month figure through Mar 2026 stood at -$325.8 million (up 18.94% YoY), and the FY2025 full-year result was -$190.9 million, up 25.77% from the prior year.
- EBT slipped to -$145.2 million in Q1 2026, from -$39.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$39.1 million in Q4 2025 to a low of -$224.9 million in Q3 2022.
- A 5-year average of -$99.9 million and a median of -$81.5 million in 2022 frame the typical range for EBT.
- Across the five-year window, EBT plunged 1436157.14% in 2022 and jumped 60.27% in 2025, its largest moves.
- Tracing ALLO's EBT over 5 years: stood at -$100.5 million in 2022, then climbed by 27.55% to -$72.8 million in 2023, then advanced by 21.0% to -$57.5 million in 2024, then jumped by 32.13% to -$39.1 million in 2025, then sank by 271.79% to -$145.2 million in 2026.
- Business Quant data shows ALLO's EBT at -$145.2 million in Q1 2026, -$39.1 million in Q4 2025, and -$65.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -145.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.21 Mn |
| Dec 31, 2025 | -39.06 Mn |
| Sep 30, 2025 | -65.29 Mn |
| Jun 30, 2025 | -76.28 Mn |
| Mar 31, 2025 | -73.75 Mn |
| Dec 31, 2024 | -57.54 Mn |
| Sep 30, 2024 | -78.68 Mn |
| Jun 30, 2024 | -191.98 Mn |
| Mar 31, 2024 | -77.68 Mn |
| Dec 31, 2023 | -72.84 Mn |
| Sep 30, 2023 | -91.53 Mn |
| Jun 30, 2023 | -113.01 Mn |
| Mar 31, 2023 | -100.03 Mn |
| Dec 31, 2022 | -100.54 Mn |
| Sep 30, 2022 | -224.93 Mn |
| Jun 30, 2022 | -109.12 Mn |
| Mar 31, 2022 | -81.52 Mn |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -160.39 Mn |
| Jun 30, 2021 | -146.94 Mn |